Senior Scientist
Merck
Rahway, New Jersey
Michael earned his BA in Chemistry (2012) at The College of New Jersey in Ewing, NJ and earned his Ph.D in Chemistry at the University of Pennsylvania in the group of Ronen Marmorstein, where he focused on utilizing biochemistry and structural biology to explore dimerization of kinases within the MAPK Signalling pathway. Following graduation, Michael started as a postdoctoral researcher at Rockefeller University in the lab of Tarun Kapoor. He utilized his skills in structural biology and biochemistry to identify small molecule probes of ATPases, particularly AAA+ proteins and DNA helicases. Later, Michael started his industry journey in the Discovery Biotherapeutics- Protein Sciences Characterization group at Bristol Myers Squibb (BMS). There, he became familiar with early discovery within biologics, screening biological drug candidates for stability and binding to help determine which candidates should be prioritized. He has since moved to Merck in the Biologics-Analytical Research & Development (B-AR&D) group in 2023, and works on method development on aggregation, and characterization techniques such as UP-SEC, CE-SDS, icIEF, N-Glycan analysis and more.
Disclosure information not submitted.
The Tale of Two Methods: Charge Heterogeneity of Stressed Biotherapeutics
Wednesday, November 12, 2025
3:30 PM - 3:45 PM CT